Abeona Therapeutics® Provides Business Update Highlighting Building Momentum in ZEVASKYN® Commercial Launch
Abeona Therapeutics Inc. (ABEO)
Last abeona therapeutics inc. earnings: 3/16 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.abeonatherapeutics.com
Company Research
Source: GlobeNewswire
CLEVELAND, March 09, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an update on the building momentum in the Company’s launch of FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treating wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Following the optimization of a release assay in 2025, ZEVASKYN commercial launch activities commenced in the fourth quarter, with the first patient treatment completed in December prior to a mandatory scheduled facility shutdown. Since resuming manufacturing in late January 2026, multiple biopsies have been collected, a patient has completed treatment with ZEVASKYN, and there are ongoing manufacturing runs. Additional biopsies are scheduled for the remainder of this quarter. “We are building toward a regular cadence of biopsy collections and are gaining visibility into more patients entering the ZEVASKYN treatment funnel
Show less
Read more
Impact Snapshot
Event Time:
ABEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABEO alerts
High impacting Abeona Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ABEO
News
- Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB [Seeking Alpha]Seeking Alpha
- Abeona Therapeutics (ABEO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.MarketBeat
- Abeona Therapeutics: Early Zevaskyn Revenue Marks A Key Inflection Point [Seeking Alpha]Seeking Alpha
- Abeona Therapeutics (ABEO) was given a new $17.00 price target by Stifel Nicolaus.MarketBeat
- Abeona Therapeutics Inc (ABEO) Q4 2025 Earnings Call Highlights: Strong Demand for Zivasskin ... [Yahoo! Finance]Yahoo! Finance
ABEO
Earnings
- 3/17/26 - Beat
ABEO
Sec Filings
- 3/20/26 - Form 8-K
- 3/17/26 - Form 10-K
- 3/17/26 - Form 8-K
- ABEO's page on the SEC website